Abstract: Compounds of Formula I, wherein R1-R8 are defined herein are provided, together with pharmaceutically acceptable salts, hydrates, metabolites, and/or prodrugs thereof. Uses of these compounds for inhibiting beta amyloid production and for the prevention and treatment of Alzheimer's Disease and Down's syndrome are described.
Compounds of Formula I, wherein R1-R8 are defined herein are provided, together with
pharmaceutically acceptable salts, hydrates, metabolites, and/or prodrugs thereof. Uses of these
compounds for inhibiting beta amyloid production and for the prevention and treatment of
Alzheimer's Disease and Down's syndrome are described.
| # | Name | Date |
|---|---|---|
| 1 | abstract-01149-kolnp-2007.jpg | 2011-10-07 |
| 2 | 1149-KOLNP-2007-CORRESPONDENCE.pdf | 2011-10-07 |
| 3 | 01149-kolnp-2007-gpa.pdf | 2011-10-07 |
| 4 | 01149-kolnp-2007-form 5.pdf | 2011-10-07 |
| 5 | 01149-kolnp-2007-form 3.pdf | 2011-10-07 |
| 6 | 01149-kolnp-2007-form 2.pdf | 2011-10-07 |
| 7 | 01149-kolnp-2007-form 18.pdf | 2011-10-07 |
| 8 | 01149-kolnp-2007-form 1.pdf | 2011-10-07 |
| 9 | 01149-kolnp-2007-description complete.pdf | 2011-10-07 |
| 10 | 01149-kolnp-2007-correspondence others.pdf | 2011-10-07 |
| 11 | 01149-kolnp-2007-correspondence others 1.2.pdf | 2011-10-07 |
| 12 | 01149-kolnp-2007-correspondence others 1.1.pdf | 2011-10-07 |
| 13 | 01149-kolnp-2007-claims.pdf | 2011-10-07 |
| 14 | 01149-kolnp-2007-assignment.pdf | 2011-10-07 |
| 15 | 01149-kolnp-2007-abstract.pdf | 2011-10-07 |
| 16 | 1149-KOLNP-2007_EXAMREPORT.pdf | 2016-06-30 |
| 17 | 1149-KOLNP-2007-ABANDONED LETER.pdf | 2017-06-22 |
| 18 | 1149-KOLNP-2007-FIRST EXAMINATION REPORT.pdf | 2018-07-03 |
| 19 | 01149-kolnp-2007-priority document.pdf | 2018-07-04 |